Published in Protein Expr Purif on March 23, 2007
MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. Prostate (2014) 0.93
Purification and preliminary X-ray crystallographic studies of beta-microseminoprotein from human seminal plasma. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.77
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71
Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res (2006) 1.43
Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry (2004) 1.05
Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J (2005) 1.02
A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer (2006) 1.00
Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun (2006) 0.98
A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis (2005) 0.95
Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs (2006) 0.90
Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. Cell Signal (2010) 0.89
Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs (2005) 0.86
Recognizing false ischemic penumbras in CT brain perfusion studies. Radiographics (2012) 0.86
Hypoxia and leucine deprivation induce human insulin-like growth factor binding protein-1 hyperphosphorylation and increase its biological activity. Endocrinology (2008) 0.84
Quantitative 2-D gel electrophoresis-based expression proteomics of albumin and IgG immunodepleted plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.84
A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res (2004) 0.84
Adapting and implementing a long-term nutrition and physical activity curriculum to a rural, low-income, biethnic community. J Nutr Educ Behav (2006) 0.83
Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance. J Proteome Res (2010) 0.81
Phosphorylation of IGFBP-1 at discrete sites elicits variable effects on IGF-I receptor autophosphorylation. Endocrinology (2013) 0.81
18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids (2002) 0.80
Altered liver secretion of vascular regulatory proteins in hypoxic pregnancies stimulate angiogenesis in vitro. J Proteome Res (2011) 0.80
Functional and complementary phosphorylation state attributes of human insulin-like growth factor-binding protein-1 (IGFBP-1) isoforms resolved by free flow electrophoresis. Mol Cell Proteomics (2009) 0.79
Effects of maternal nutrient restriction, intrauterine growth restriction, and glucocorticoid exposure on phosphoenolpyruvate carboxykinase-1 expression in fetal baboon hepatocytes in vitro. J Med Primatol (2013) 0.79
Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction. Endocrinology (2014) 0.79
Site specific phosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) for evaluating clinical relevancy in fetal growth restriction. J Proteome Res (2009) 0.79
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol (2008) 0.78
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer (2005) 0.76
Identification, recognition and misidentification syndromes: a psychoanalytical perspective. Front Psychol (2013) 0.75
Nucleosomes bind fibroblast growth factor-2 for increased angiogenesis in vitro and in vivo. Mol Cancer Res (2004) 0.75
[Medical and social characteristics and treatment plans for brain-damaged patients hospitalized]. Sante Publique (2008) 0.75